Goldtam-D Tablet SR contains a combination of Tamsulosin 0.4 mg and Dutasteride 0.5 mg, formulated for the treatment of benign prostatic hyperplasia (BPH). Tamsulosin is an alpha-1 adrenergic receptor antagonist that selectively relaxes the smooth muscle in the prostate and bladder neck, improving urine flow and reducing symptoms of urinary obstruction. Dutasteride is a 5-alpha-reductase inhibitor that decreases the conversion of testosterone to dihydrotestosterone (DHT), a hormone responsible for prostate enlargement. The sustained-release formulation ensures a gradual release of the active ingredients, promoting consistent plasma levels and enhancing therapeutic efficacy while minimizing side effects. Goldtam-D is indicated for men with moderate to severe BPH to improve urinary symptoms and reduce the risk of acute urinary retention and the need for surgical intervention. It is essential to use this medication under medical supervision, as it may cause side effects such as dizziness, headache, decreased libido, or ejaculation disorders. Patients should be monitored for prostate-specific antigen (PSA) levels, as Dutasteride can affect PSA readings. This combination therapy offers a dual mechanism of action, providing symptomatic relief and addressing the underlying pathophysiology of BPH, thereby improving quality of life in affected individuals.